• +1-646-491-9876
    • +91-20-67278686

    Search

    Tissue Factor Pathway Inhibitor Pipeline Review H2 2017

    Tissue Factor Pathway Inhibitor Pipeline Review H2 2017

    • Report Code ID: RW0001884166
    • Category Pharmaceuticals
    • No. of Pages 33
    • Publication Month Jul-17
    • Publisher Name Global Markets Direct
    Tissue Factor Pathway Inhibitor (Extrinsic Pathway Inhibitor or EPI or Lipoprotein Associated Coagulation Inhibitor or LACI or TFPI) - Pipeline Review, H2 2017

    Summary

    Tissue Factor Pathway Inhibitor (Extrinsic Pathway Inhibitor or EPI or Lipoprotein Associated Coagulation Inhibitor or LACI or TFPI) - Tissue factor pathway inhibitor (TFPI) is a single-chain polypeptide. It inhibits factor Xa directly and in a Xa-dependent way, inhibits VIIa/tissue factor activity. It has an antithrombotic action and also the ability to associate with lipoproteins in plasma.

    Tissue Factor Pathway Inhibitor (Extrinsic Pathway Inhibitor or EPI or Lipoprotein Associated Coagulation Inhibitor or LACI or TFPI) pipeline Target constitutes close to 5 molecules. Out of which approximately 5 molecules are developed by Companies.The molecules developed by companies in Phase II, Phase I and Preclinical stages are 2, 1 and 2 respectively. Report covers products from therapy areas Hematological Disorders which include indications Hemophilia A, Hemophilia B and Hemophilia.

    The latest report Tissue Factor Pathway Inhibitor - Pipeline Review, H2 2017, outlays comprehensive information on the Tissue Factor Pathway Inhibitor (Extrinsic Pathway Inhibitor or EPI or Lipoprotein Associated Coagulation Inhibitor or LACI or TFPI) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA) , route of administration (RoA) and molecule type. It also reviews key players involved in Tissue Factor Pathway Inhibitor (Extrinsic Pathway Inhibitor or EPI or Lipoprotein Associated Coagulation Inhibitor or LACI or TFPI) targeted therapeutics development with respective active and dormant or discontinued projects.

    The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

    Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

    Scope

    - The report provides a snapshot of the global therapeutic landscape for Tissue Factor Pathway Inhibitor (Extrinsic Pathway Inhibitor or EPI or Lipoprotein Associated Coagulation Inhibitor or LACI or TFPI)
    - The report reviews Tissue Factor Pathway Inhibitor (Extrinsic Pathway Inhibitor or EPI or Lipoprotein Associated Coagulation Inhibitor or LACI or TFPI) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
    - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
    - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
    - The report reviews key players involved in Tissue Factor Pathway Inhibitor (Extrinsic Pathway Inhibitor or EPI or Lipoprotein Associated Coagulation Inhibitor or LACI or TFPI) targeted therapeutics and enlists all their major and minor projects
    - The report assesses Tissue Factor Pathway Inhibitor (Extrinsic Pathway Inhibitor or EPI or Lipoprotein Associated Coagulation Inhibitor or LACI or TFPI) targeted therapeutics based on mechanism of action (MoA) , route of administration (RoA) and molecule type
    - The report summarizes all the dormant and discontinued pipeline projects
    - The report reviews latest news and deals related to Tissue Factor Pathway Inhibitor (Extrinsic Pathway Inhibitor or EPI or Lipoprotein Associated Coagulation Inhibitor or LACI or TFPI) targeted therapeutics

    Reasons to buy

    - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
    - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
    - Identify and understand the targeted therapy areas and indications for Tissue Factor Pathway Inhibitor (Extrinsic Pathway Inhibitor or EPI or Lipoprotein Associated Coagulation Inhibitor or LACI or TFPI)
    - Identify the use of drugs for target identification and drug repurposing
    - Identify potential new clients or partners in the target demographic
    - Develop strategic initiatives by understanding the focus areas of leading companies
    - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
    - Devise corrective measures for pipeline projects by understanding Tissue Factor Pathway Inhibitor (Extrinsic Pathway Inhibitor or EPI or Lipoprotein Associated Coagulation Inhibitor or LACI or TFPI) development landscape
    - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
    Table of Contents
    List of Tables
    List of Figures
    Introduction
    Publisher Report Coverage
    Tissue Factor Pathway Inhibitor (Extrinsic Pathway Inhibitor or EPI or Lipoprotein Associated Coagulation Inhibitor or LACI or TFPI) - Overview
    Tissue Factor Pathway Inhibitor (Extrinsic Pathway Inhibitor or EPI or Lipoprotein Associated Coagulation Inhibitor or LACI or TFPI) - Therapeutics Development
    Products under Development by Stage of Development
    Products under Development by Therapy Area
    Products under Development by Indication
    Products under Development by Companies
    Tissue Factor Pathway Inhibitor (Extrinsic Pathway Inhibitor or EPI or Lipoprotein Associated Coagulation Inhibitor or LACI or TFPI) - Therapeutics Assessment
    Assessment by Mechanism of Action
    Assessment by Route of Administration
    Assessment by Molecule Type
    Tissue Factor Pathway Inhibitor (Extrinsic Pathway Inhibitor or EPI or Lipoprotein Associated Coagulation Inhibitor or LACI or TFPI) - Companies Involved in Therapeutics Development
    Bayer AG
    Green Cross Corp
    Novo Nordisk A/S
    Pfizer Inc
    Shire Plc
    Tissue Factor Pathway Inhibitor (Extrinsic Pathway Inhibitor or EPI or Lipoprotein Associated Coagulation Inhibitor or LACI or TFPI) - Drug Profiles
    BAY-1093884 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    concizumab - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    MG-1113A - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    PF-06741086 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Synthetic Peptide to Inhibit TFPI for Hemophilia - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Tissue Factor Pathway Inhibitor (Extrinsic Pathway Inhibitor or EPI or Lipoprotein Associated Coagulation Inhibitor or LACI or TFPI) - Dormant Products
    Tissue Factor Pathway Inhibitor (Extrinsic Pathway Inhibitor or EPI or Lipoprotein Associated Coagulation Inhibitor or LACI or TFPI) - Discontinued Products
    Tissue Factor Pathway Inhibitor (Extrinsic Pathway Inhibitor or EPI or Lipoprotein Associated Coagulation Inhibitor or LACI or TFPI) - Product Development Milestones
    Featured News & Press Releases
    Nov 30, 2015: New Data from Bayer's Portfolio in Hematology to be Presented at ASH 2015
    Oct 30, 2015: MorphoSys Announces Clinical Milestone in Hemophilia Program with Bayer HealthCare
    Feb 06, 2007: Jerini Expands Collaboration With Baxter To Develop Non-intraveneous Hemophilia Therapy
    May 22, 2006: Baxter And Jerini Find Candidates For Development In Hemophilia
    May 18, 2006: Baxter And Jerini Advance Program To Develop Non-Intravenous Hemophilia Therapy
    Appendix
    Methodology
    Coverage
    Secondary Research
    Primary Research
    Expert Panel Validation
    Contact Us
    Disclaimer

    List of Tables

    Number of Products under Development by Stage of Development, H2 2017
    Number of Products under Development by Therapy Areas, H2 2017
    Number of Products under Development by Indication, H2 2017
    Number of Products under Development by Companies, H2 2017
    Products under Development by Companies, H2 2017
    Number of Products by Stage and Mechanism of Actions, H2 2017
    Number of Products by Stage and Route of Administration, H2 2017
    Number of Products by Stage and Molecule Type, H2 2017
    Pipeline by Bayer AG, H2 2017
    Pipeline by Green Cross Corp, H2 2017
    Pipeline by Novo Nordisk A/S, H2 2017
    Pipeline by Pfizer Inc, H2 2017
    Pipeline by Shire Plc, H2 2017
    Dormant Projects, H2 2017
    Discontinued Products, H2 2017

    List of Figures

    Number of Products under Development by Stage of Development, H2 2017
    Number of Products under Development by Indications, H2 2017
    Number of Products by Stage and Mechanism of Actions, H2 2017
    Number of Products by Routes of Administration, H2 2017
    Number of Products by Stage and Routes of Administration, H2 2017
    Number of Products by Molecule Types, H2 2017
    Number of Products by Stage and Molecule Types, H2 2017
    Bayer AG
    Green Cross Corp
    Novo Nordisk A/S
    Pfizer Inc
    Shire Plc

    Request for Sample

    Report Url http://www.reportsweb.com//tissue-factor-pathway-inhibitor-pipeline-review-h2-2017&type=sample
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire before Buying

    Report Url http://www.reportsweb.com//tissue-factor-pathway-inhibitor-pipeline-review-h2-2017&type=buying
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire for Discount

    Report Url http://www.reportsweb.com//tissue-factor-pathway-inhibitor-pipeline-review-h2-2017&type=discount
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments